Please ensure Javascript is enabled for purposes of website accessibility

Zogenix Soars 10% Today Despite Diluting Investors

By Todd Campbell - Oct 2, 2017 at 1:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After reporting positive phase 3 results for its drug for Dravet syndrome last week, management announced a dilutive stock offering today to raise more capital.

What happened

After the company announced it will tap investors for money to fuel R&D (research and development) and pre-commercialization efforts for its Dravet syndrome drug, shares in Zogenix (ZGNX) are rallying 10% at 2 p.m. EDT today.

So what

Zogenix rolled out impressive phase 3 study data last week, showing its ZX008 can significantly reduce the number of monthly seizures in people diagnosed with Dravet syndrome, a rare form of child-onset epilepsy.

Gold and silver pills spill out of a large gold and silver pill onto a pile of paper money.

IMAGE SOURCE: GETTY IMAGES.

Dravet syndrome patients receiving ZX008 saw the average number of monthly seizures fall by 72%, compared to just a 13% decline in seizures for patients receiving a placebo. The findings were particularly encouraging because the safety profile appears OK, with the rate of severe adverse events being similar between the ZX008 and placebo cohorts.

The positive data sent shares soaring higher, and on Monday, management announced it will tap into investor enthusiasm to solidify its balance sheet. The company will offer 4.3 million shares for purchase, plus an additional 645,000 shares to cover any overallotments associated with the stock offering.

Now what

A second phase 3 trial of ZX008 in Dravet syndrome should read out data early next year; if it's also positive, then Zogenix plans to file for approval from the U.S. Food and Drug Administration. In the meantime, the company is planning to begin enrolling another phase 3 trial evaluating ZX008 in Lennox-Gastaut syndrome, a more common form of childhood-onset epilepsy. Wins in both Dravet syndrome and Lennox-Gastaut syndrome would position the company to compete against GW Pharmaceuticals (GWPH), a drugmaker working on marijuana-based treatments for epilepsy.

GW Pharmaceuticals has reported positive phase 3 outcomes for its cannabidiol drug Epidiolex, in both Dravet syndrome and Lennox-Gastaut syndrome, and an FDA filing should happen soon. In its trials, Epidiolex reduced monthly seizures from baseline by about 40%.

Zogenix hasn't announced pricing for its stock offering yet, but the money that's raised will go toward R&D, preparation for a regulatory submission, and prelaunch commercial efforts.

While Dravet syndrome is uncommon, the broader epilepsy population is a billion-dollar market. If Zogenix can demonstrate ZX008 is effective in various forms of epilepsy, it could wind up with a big seller on its hands.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zogenix, Inc. Stock Quote
Zogenix, Inc.
ZGNX
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.